China Retaliates Against European Union Device Manufacturers
Imposes a ban on European medical devicesGrowing China-EU Trade Conflict
The medical device industry is now the latest battleground in a growing China-EU trade conflict – with potential ripple effects across global supply chains and health procurement markets.
The AP reports that in an escalating trade dispute, China has barred European medical device companies from participating in government procurement contracts over 45 million yuan ($6.28 million). The ban, announced Sunday by China’s Finance Ministry, took effect immediately and is seen as retaliation for European Union trade restrictions on Chinese products.
Key Details:
- The ban applies only to non-Chinese-manufactured EU products.
- EU firms that produce within China are exempt.
- It mirrors a June EU policy excluding Chinese companies from public procurement over €5 million.
Broader EU-China Trade Tensions
- On Friday, China imposed anti-dumping duties on European brandy, particularly affecting French cognac.
- China is also investigating EU pork and dairy imports following EU actions targeting Chinese electric vehicles (EVs).
- The EU claims China’s procurement process discriminates against foreign firms, citing legal and administrative barriers.
China’s Response
China’s Ministry of Commerce said it had shown goodwill and willingness to negotiate but accused the EU of ignoring diplomatic overtures and erecting new protectionist barriers.
Read more here.
FDA Information – Conveniently Organized and Accessible
Quickly find the FDA information you need Conveniently organized FDA information. The U.S. Food and Drug Administration (FDA) provides a wealth of information for consumers and industry stakeholders. The problem is, it can be difficult to navigate to the information...
Hospira Recalls Antibiotic for Presence of Glass Particles
Hospira, Inc., a division of Pfizer, announced a Class I recall of its Vancomycin Injection product due to visible glass particles that were identified in one vial of the drug. The recall involves lot 33045BA of Vancomycin Hydrochloride Injection USP 1.5g single dose...
Three Companies Recall Blood Pressure Medication
All recalled products had unacceptable levels of nitrosamines Three pharmaceutical manufacturers have recalled batches of the blood pressure drug quinapril this year for exceeding safe levels of nitrosamines. Luprin Pharmaceuticals, Aurobindo Pharma USA, and Pfizer...